Lipocine (NASDAQ:LPCN) Director John Higuchi Buys 40,000 Shares

Lipocine Inc. (NASDAQ:LPCN) Director John Higuchi bought 40,000 shares of the business’s stock in a transaction that occurred on Tuesday, April 7th. The shares were acquired at an average price of $2.03 per share, for a total transaction of $81,200.00. Following the transaction, the director owned 203,797 shares in the company, valued at $413,707.91. This represents a 24.42% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website.

Lipocine Price Performance

Shares of Lipocine stock opened at $2.00 on Wednesday. Lipocine Inc. has a one year low of $1.81 and a one year high of $12.37. The stock’s 50-day moving average is $7.93 and its 200 day moving average is $5.77. The firm has a market cap of $14.60 million, a price-to-earnings ratio of -1.19 and a beta of 1.09.

Lipocine (NASDAQ:LPCN) last announced its earnings results on Tuesday, March 10th. The specialty pharmaceutical company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.60) by $0.26. Lipocine had a negative return on equity of 59.30% and a negative net margin of 487.00%.The company had revenue of $1.15 million for the quarter, compared to analyst estimates of $0.12 million.

Institutional Investors Weigh In On Lipocine

Large investors have recently added to or reduced their stakes in the business. Ikarian Capital LLC purchased a new position in Lipocine during the fourth quarter worth about $1,602,000. Squadron Capital Management LLC bought a new position in shares of Lipocine in the 4th quarter worth $4,256,000. Boothbay Fund Management LLC bought a new position in Lipocine in the fourth quarter valued at $441,000. Diadema Partners LP bought a new stake in Lipocine during the fourth quarter worth about $2,095,000. Finally, Persistent Asset Partners Ltd purchased a new position in shares of Lipocine in the 4th quarter worth about $567,000. Institutional investors own 9.11% of the company’s stock.

Lipocine News Summary

Here are the key news stories impacting Lipocine this week:

• Positive Sentiment: Company insiders increased stakes — CEO Mahesh Patel bought 25,000 shares (~$2.03 avg) and director John W. Higuchi bought 123,000 shares, signaling insider confidence and providing buy-side support to the stock. Mahesh Patel Purchases 25,000 Shares of Lipocine (NASDAQ:LPCN) Stock
• Neutral Sentiment: HC Wainwright updated models upward — the firm raised FY2026 and quarterly EPS forecasts (e.g., FY2026 to ($1.91) from ($2.27) and several quarter EPS revisions) but keeps a “Neutral” rating, an outcome that reduces downside in estimates but does not convert to an upgrade. MarketBeat summary of analyst estimates
• Neutral Sentiment: Recent quarterly results showed a revenue beat and narrower-than-expected EPS loss (reported ($0.34) vs consensus ($0.60)), which supports the revised analyst estimates but the company remains loss-making and small-cap volatility is high. MarketBeat financial summary
• Negative Sentiment: HC Wainwright appears to have reduced its stance in a separate report (MSN coverage) — any downgrade or more cautious wording from a specialist biotech/healthcare desk can prompt short-term selling in a low-float name like LPCN. HC Wainwright & Co. downgrades Lipocine (LPCN)
• Negative Sentiment: Shareholder litigation inquiry — Johnson Fistel announced an investigation into potential claims involving Lipocine executives; legal risk and potential costs can weigh on sentiment and valuation. Johnson Fistel investigation announcement

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on LPCN shares. Wall Street Zen raised Lipocine from a “sell” rating to a “hold” rating in a research note on Sunday, March 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lipocine in a report on Friday, March 27th. Finally, HC Wainwright reiterated a “neutral” rating on shares of Lipocine in a report on Monday. One research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $15.00.

Lipocine Company Profile

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.